INTRODUCTION
Autoimmune hepatitis (AIH) is a progressive in flammatory liver disorder characterized by hypergam maglobulinemia, circulating autoantibodies, and histological evidence of a florid mononuclear cell in filtration, which is referred to as interface hepatitis [1, 2] . AIH type 1 (AIH1) is distinguished by the presence of circulating antinuclear antibodies (ANAs) and/or smooth muscle antibodies (SMAs), and is the predominant form of AIH in adults. Although genetic factors, such as human leucocyte antigen HLADR3 and HLADR4 are associated with the development of AIH, Other factors contributing to the aetiology and the pathogenic process of AIH remains unclear. While most patients with AIH respond well to immunosuppressive therapy, about 10%20% of the cases still progress to cirrhosis and require the liver transplantation [3, 4] . Therefore, It is important to understand the pathogenesis of AIH in the management of patients with AIH.
Although the pathogenic initiating events are unknown, AIH1 is believed to be mediated by CD4 T cells that recognize one or more liverspecific self antigenic peptides, and histological evidences show the presence of interferonγ (IFNγ)producing T helper type 1 (Th1) cells in liver [5, 6] . These imply the importance of Th1like immune response in the pathogenesis of AIH. A recent study suggests that B cells also contribute to the development and progression of AIH [7] . Activated B cells can differentiate into CD38
+ plasma cells that secrete antibodies, such as ANA and SMA [8, 9] . B effector 1 cells (Be1) can function as antigen presenting cells to present antigen determinants to trigger Tcell activation and secrete IFNγ to regulate autoimmunity [10, 11] . The Tbox transcription factor, Tbet, is required for IFNγ production and the generation of type 1 immunity [12] . Initial studies demonstrated that Tbet is expressed in developing the Th1 cells and mediates IFNγ production, Th1 differentiation, and repression of the alternative Th2 program [13] . Recent studies have highlighted the importance of Tbet in other cellular subtypes implicated in the type 1 immune response, such as dendritic cells, natural killer (NK) cells, natural killer T (NKT) cells, and CD8 + T cells. Tbet has also been shown to regulate IFNγ production by Be1 cells [14, 15] . The high level of Tbet production which is associated with increased numbers of IFNγproducing B cells have been identified in the blood and lymphoid tissues of mice and humans with autoimmune dis orders, such as systemic lupus erythematosus (SLE) and rheumatoid arthritis [10, 11] . Furthermore, high Tbet production is associated with the pathogenesis of Tcell mediated liver injury in conA murine model [16] . Tbet deficient mice immunized with myelin oligodendrocyte glycoprotein were resistant to the development of experimental autoimmune encephalomyelitis [17] . In a murine lupus model, the absence of Tbet strikingly reduces B celldependent manifestations, including autoantibody production, hypergammaglobulinemia, and immunecomplex renal disease, and abrogates IFNγmediated IgG2a production [18] . Although the role of Tbet has been studied in a variety of autoimmune diseases in mice, its relative importance in human AIH is not characterized.
Genetic variations in the nucleotide sequences of promoters can contribute to the altered expression of genes in complex inherited diseases [19, 20] . In this regard, a genetically induced increase in Tbet production may result in the expansion of either polarized Th1 cells to promote the type 1 immune response or the Be1 cell compartment to gain a greatly enhanced T cell activation capability. Three single nucleotide polymorphisms (SNPs) at 1993(C/T), 1514(C/T), and 999(G/A) sites of the TBX21 gene (encoding Tbet) promoter have been identified [21] . We have previously found that the T1993C variant, which increased the transcription factor YY1 binding to the TBX21 promoter in Jurkat T cell lines, subsequently caused lower transactivation of the promoter [22] . Furthermore, our casecontrol study (84 cases and 318 control subjects) demonstrated that TBX21 T1993C SNP was associated with susceptibility to AIH1 [23] . Individuals carrying the 1993C allele had a decreased risk to AIH1 compared with those without the 1993C allele (OR = 0.22; 95%CI: 0.090.56; P = 0.0016). Recently, the TBX21 T1993C variant has been shown to be associated with a significant decrease in Tbet expression and IFNγ production by stimulated peripheral blood CD4 + T cells from healthy participants [24] . In the present study, we further determined the characterization of transcription factor binding to the T1993C SNP site of the TBX21 promoter in CD4+ T and B cell lines. In addition, we measured the expression of Tbet and IFNγ in peripheral blood CD4 + T cells and B cells from active AIH1 patients carrying 1993TC and 1993TT genotypes, compared with healthy controls carrying 1993TC and 1993TT genotypes, in an attempt to explore the mechanism of the association between the TBX21 T1993C promoter polymorphism and AIH1 development.
MATERIALS AND METHODS

Subjects
A total of 20 patients with new onset were enrolled in this study at Southwest Hospital (Chongqing, China).
Of these 20 patients, 5 were carriers of the 1993TC genotype and 15 were carriers of the 1993TT genotype. All the patients fulfilled the criteria for AIH according to the 1999 revised scoring system of the International Autoimmune Hepatitis Group (IAIHG) [25] and were therefore found to be eligible for the study. Only pretreatment scores were analyzed. A definite diagnosis of AIH based on the IAIHG criteria requires a pretreatment score exceeding 15. Patients were excluded from the study if there was histological evidence of cholangitis or nonalcoholic steatohepatitis. In addition, patients who were positive for hepatitis B virus (HBV)surface antigen (HBsAg) or hepatitis C virus (HCV)RNA were also excluded. Patients with other causes of liver disease, such as excess alcohol or drug use, or those who had received immune suppressive therapies or glucocorticoid therapies within the past 6 mo were excluded based on reviews of their appropriate history and investigations. The control population comprised 35 healthy Chinese Han adults, who were volunteer blood donors from Chongqing, China. They were matched with type 1 AIH patients for age, gender, and TBX21 genotyping (101993TC and 251993TT genotype carriers), and had no history of any chronic inflammatory disease. All subjects provided written consent to participate in the present study. This study was approved by the Ethics Committee of Southwest Hospital, Chongqing. The demographic and clinical characteristics of these subjects are shown in Table 1 .
Clinical examination
The clinical data of each subject were collected from the hospital records. These data included age, sex and age at diagnosis, time of onset of symptoms or other evidence of liver disease, markers of infection with hepatitis viruses HBV and HCV, alcohol intake, coexisting autoimmune diseases, serum levels of alanine transaminase (ALT), aspartate aminotransferase (AST), alkaline phosphatase and bilirubin, and full blood cell counts. Autoantibodies were determined by indirect immunofluorescence on murine tissue sections (EuroImmun Medizinische Labordiagnostika AG, Lübeck, Germany), and a serum titer of 1:100 or greater was considered positive for all antibodies. All patients underwent liver biopsies to evaluate disease activity at the time of entry. The histological diagnosis of cirrhosis required a loss of the normal lobular architecture, reconstruction of hepatic nodules and presence of regenerative nodules.
Cell culture and peripheral blood mononuclear cell isolation
Jurkat cells (CD4 + human T lymphoblasts) and Raji cells (human B lymphocytes) were cultured in RPMI 1640 medium supplemented with 10% fetal calf serum, 2 mmol/L glutamine, 100 U/mL penicillin and 50 mg/mL streptomycin as described previously [23] . pCMV6XL5 was added into the cell suspension. The luciferase activity was measured, as described previously [22] .
siRNA-mediated suppression of YY1 expression in the PBMCs of AIH-1 patients
The isolated PBMCs were plated at a density of 10 6 cells/ml as described above. siRNA targeted against YY1 (sc36864) and siRNA consisting of a scrambled sequence that would not lead to specific degradation of any cellular message (control) were purchased from Santa Cruz Biotechnology. The cells in 1 mL of medium were incubated in 5 mmol/L YY1siRNA in the Nucleofector transfection reagent at room temperature with gentle agitation. Two hours after transfection, fresh medium was added to provide the cells with sufficient nutrients, and the transfected cells were harvested after 48 h for RNA extraction.
RNA isolation and real-time PCR analysis of the mRNA expression levels of YY1, T-bet and IFN-γ
The Trizolpurified (Sangon, China) total RNA (2 μg) from PBMCs was used for cDNA synthesis with the RevertAidTM First Strand cDNA Synthesis Kit (Fermentas, Canada) following the manufacturer's instructions. The mRNA expression levels of IFNγ and of nuclear factors such as YY1 and Tbet were quantified by realtime PCR, and the level of βactin mRNA was also detected as an internal control for each sample. The relative mRNA expression levels of genes were determined using the comparative (2ΔΔCt) method.
The following primer sequences were used for this analysis: IFNγ 5'TCAGATGTAGCGGATAATGGAAC3' a n d
' T T C C T T G A T G G T C T C C A C A C T C 3 ' ; T b e t ' C C C A C T T T G A A C AT C A G G C A G A 3 ' a n d ' C A G C A C AT C T T T T G A G G T T G G
A G 3 ' ; 5 ' Y Y 1 G G ATA A C TC G G C C A T G A G A A 3 ' a n d 5'ATAGGGCCTGTCTCCGGTAT3'.
T-bet and IFNγ expression by flow cytometry
The experiments were performed on whole blood using the BD FastImmune CD4 Intracellular Cytokine Detection Kit (cat# 340970, BDIS, San Jose, CA, United States) according to the manufacturer's instructions. In order to identify Th1 and B effector cells, 0.5 mL heparinized whole blood was stimulated with 2.5 μg/mL PMA and either the antiCD28/ant CD49d costimulatory monoclonal antibodies (final concentration of 1 μg/mL) or IFNα2b (2000 U/mL, ScheringPlough, United States) [26] . 
Electrophoretic mobility shift assay
The electrophoretic mobility shift assay (EMSA) was performed by the method described previously [22] . The synthesized oligonucleotides (5'TACGGAGAAA TGG(T)GGGTAAGGTGTTG3' corresponding to the 2006/1980 region of the human TBX21 gene with 1993T) and 5'TACGGAGAAATGG(C)GGGTAAGGT GTTG3', 1993C), labeled with biotin at the 5'end, were annealed to the complementary oligonucleotide labeled with biotin at the 5'end. Nuclear extracts were prepared from Jurkat and Raji cells as described previously. For the competition assay, non labeled double stranded DNA (dsDNA) fragments consisting of the following sequences were used: YY1 5'CGCTCCCCGGCCATCTTGGCGGCTGGT3', and the sequences containing 1993T or 1993C. Supershifts were performed with antibodies to YY1, C/EBPβ (N10) and cJun (N) that were purchased from Santa Cruz Biotechnology. All EMSA experiments were repeated more than three times, and a representative result for each experiment is shown.
Chromatin immunoprecipitation
The chromatin immunoprecipitation (ChIP) assay was performed using the ChIPIT Express kit (Active Motif, Carlsbad, CA, United States) as described previously [22] . The following antibodies were used: a rabbit antiYY1 (C20; Santa Cruz Biotechnology), antiCJun (N; Santa Cruz Biotechnology), antC/EBPβ (Santa Cruz Biotechnology) and a nonspecific rabbit IgG (Santa Cruz Biotechnology). PCR was performed with the following primer, which were designed to amplify the 2048 to 1912 region of the TBX21 promoter: 5'CCCACTTTGAACATCAGGCAGA3' and 5'CAGCACATCTTTTGAGGTTGGAG3'.
Plasmid constructs
A reporter plasmid carrying luciferase gene under the control of a 2.2kb TBX21 promoter fragment carrying the 1993T or 1993C allele was used as described previously [22] . The pCMVYY1 vector expressing fullsize YY1 and its control pCMV6XL5 were obtained from OriGene. 
Cell transfection and luciferase assay
Statistical analysis
Data are expressed as mean ± SD. All statistical analyses were performed in SPSS 19.0 software. The difference between the groups was analyzed by parametric Student's ttest or nonparametric Mann Whitney U test. Correlations were examined by Pearson correlation. P values < 0.05 were considered significant.
RESULTS
General information
To determine the potential role of CD4+ T and B cells in the pathogenesis of AIH, 20 patients with active AIH and 35 gender and agematched healthy controls were recruited. There was no significant difference in the distribution of age and gender between the patients and healthy controls ( Table 1) . As expected, the concentrations of serum ALT and AST and total bilirubin in the patients were significantly higher than that in the healthy controls. Furthermore, 15 of 20 patients with active AIH were positive for anti ANA antibodies, three were positive for antiSMA antibodies, and two were positive for both. In addition, abnormally higher levels of serum IgG were detected in the patients, demonstrating the liver damage and hypergammaglobulinaemia in the AIH1 patients.
Binding profile of transcription factor to the T-1993C polymorphism site in CD4 + T and B cells
The results of EMSA showed the formation of two specific DNAprotein complexes (1 and 2) for both 1993T and 1993C allelic probes ( Figure 1A and B). The addition of antibody against YY1 led to abrogation of only complex 2 in both the 1993T and 1993C probes ( Figure 1A , lanes 3 and 4; Figure 1B , lanes 9 and 10), suggesting that YY1 participates in complex 2 formation. AP1, HSF1 and C/EBPβ did not seem to be involved in the formation of complexes 1 and 2 ( Figure 1A , lanes 510; Figure 1B , lanes 38). A competition assay was performed to confirm whether the 1993C probe interacted more efficiently with the YY1 protein compared with the 1993T. It was found that the complexes formed with the 1993C probe were consistently more intense than these with 1993T ( Figure 1C) , which was consistent with the results of our study using Jurkat T cells [22] . In comparison with complex 1, we also observed that complex 2 required higher concentrations of competitors to diminish its band intensity. These data indicate that the complexes contain sequencespecific DNAbinding proteins and that the T1993C SNP resides in a functionally important nucleotide, and is perhaps more relevant for complex 2.
ChIP assay was performed to further determine if YY1 binds to the T1993C element of the TBX21 promoter in vivo. PCR amplification with the primers specific to the TBX21 promoter region, wherein the YY1binding sites exist at the T1993C locus, demonstrated a 137bp product in both Jurkat and Raji chromatin after immunoprecipitation with the anti YY1 antibody, but not with the antC/EBPβ and ant CJun antibodies, or rabbit IgG ( Figure 1D ). These results demonstrate the direct interaction of YY1 with the TBX21 promoter in a noncellspecific manner.
Transcriptional effect of YY1 at the T-1993C polymorphism site on the TBX21 promoter in CD4 + T and B cells
Luciferase reporter assay was performed to study transcriptional regulation of the TBX21 promoter constructs carrying either the 1993T or 1993C allele in the Jurkat T cell and Raji B cell lines. The luciferase activity derived from the 1993T promoter was significantly higher than that from the 1993C promoter in both cell lines (P < 0.01) (Figure 2 ). These data indicate that TBX211993C is significantly less active than the 1993T allele in a noncellspecific manner. We further examined whether the transfection of a YY1 expression vector induced changes in the promoter activity of the 1993T and 1993C constructs in both Jurkat T cells and Raji B cells. We found that the luciferase activity derived from the 1993T promoter was 4fold lower in the presence of overproduced YY1, and that from the 1993C promoter decreased only by approximately 2fold (P < 0.01) (Figure 2 ). These results demonstrated that the YY1 motif upstream of the T1993C polymorphism plays a strong negative regulatory role in the activity of the TBX21 promoter, and the 1993C promoter responds to YY1 better than the 1993T promoter.
Association of IFN-γ and T-bet expression of circulating
CD4 + T cells and B cells with AIH-1 activity
Flow cytometric analysis revealed that the Tbet expression of circulating CD4 + T cells and CD20 + B cells in active AIH1 patients was significantly greater than that in controls (Z = 3.92, P < 0.01, Z = 2.43, P < 0.05,) ( Figure 3A and C). The levels of IFNγ production in circulating CD4 + T cells and CD20+ B cells from active AIH1 patients were significantly higher than that from controls (Z = 4.89, P < 0.01; Z = 2206, P < 0.05) ( Figure 3B and D). These data indicate an involvement of Th1 inflammation in Chinese patients with active AIH1. The disease activity, represented by the IAIHG score, was positively correlated with Tbet expression in CD4 + T cells and 
T-bet and IFN-γ expression of circulating CD4 + T and B cells in -1993TT homozygous and -1993TC heterozygous patients with active AIH-1
Flow cytometry was performed to analyze Tbet expression and IFNγ production in circulating T cells and B cells from AIH1 patients carrying 1993TC and 1993TT genotypes, and from healthy controls carrying 1993TC and 1993TT genotypes (Figure 4) . The Tbet expression in CD4 + T cells and CD20+ B cells was significantly higher in the 1993TT patients than in the 1993TC patients and the 1993TT controls (Z = 2.75, P < 0.01; Z = 4.33, P < 0.01; Z = 4.21, P < 0.01; Z = 2.75, P < 0.05 respectively) ( Figure 5AD ). No significant difference in Tbet expression was observed between in the 1993TC patients and 1993TC controls in both CD4 + T cells and CD20 + B cells. The levels of IFNγ production was significantly higher in CD4 + T cells and CD20 + B cells from the 1993TT patients than from the 1993TC patients and the 1993TT controls (Z = 4.16, P < 0.01; Z = 5.07, P < 0.01; Z = 3.274, P < 0.01; Z = 2.529, P < 0.05 respectively) ( Figure  5AD ). No significant difference in IFNγ production was observed between in the 1993TC patients and 
Effect of YY1 knockdown on T-bet and IFN-γ expression in the peripheral blood of AIH-1 patients
Knockdown of YY1 with siRNA was performed to analyze whether YY1 affects Tbet and IFNγ expression of circulating CD4 + T and B cells in AIH1
patients. Realtime PCR assay showed that YY1 siRNA significantly lowered the YY1 mRNA level in PBMCs from AIH patients (t = 13.83, P < 0.01) ( Figure 6 ). The levels of Tbet and IFNγ mRNA were upregulated in the YY1siRNA PBMCs compared with that in the controlsiRNA PBMCs (t = 7.61; t = 12.11, P < 0.01 respectively) ( Figure 6 ). These results suggested that YY1 affects type 1 immunity of AIH1 patients by Tbetmediated regulation.
DISCUSSION
Alterations in Tcell function and cytokines have been demonstrated to play a central role in AIH [2, 27] . In human, liver tissue injury in AIH is also mediated by CD4 + and CD8 + T cells [28] . Tbet plays a critical role in both the development and maintenance of Th1 cells, and has been proved to be a positive transcriptional regulator of IFNγ production in CD4 + T cells, CD8 + T cells, and B effector cells [15] . Prominent Tbetpositive lymphocytes have been found in both the lobular and portal infiltrate of human AIH [29] . Tbet together with IFNγ were highly expressed in the inflamed liver tissue of a mouse model of fatal AIH [30] . To date there are no data concerning the expression of Tbet in circulating lymphomononuclear cells from AIH patients. Previous studies have indicated that the Th1/Th2 balance in peripheral blood of AIH patients is shifted towards Th1 cytokines and circulating cytochrome P4502D6specific CD4
+ T cells producing IFNγ are present in AIH patients [31] . In this study, we first showed that active AIH1 patients exhibited higher Tbet and IFNγ expression in peripheral blood CD4 + T cells than healthy controls.
The increased expression of Tbet was associated with an increased production of IFNγ by peripheral blood polarization in the pathogenesis of AIH1. We found that the Tbet expression and IFNγ production of cir culating CD20+ B cells in AIH1 patients increased significantly compared with that in the controls, which was consistent with other studies that demonstrated an elevation of Tbet and IFNγ expression in circulating B cells from patients with other autoimmune diseases, such as coeliac disease and SLE [32, 33] . Moreover, Tbet expression levels in peripheral blood T and B cells were directly correlated with the IAIHG score, suggesting an association between circulating Tbetexpressing T cells or B cells and disease activity. Tbet is expressed at low levels in naive B cells, but B cells in the presence of polarized Th1 cells and antigens were able to develop into highIFNγproducing B cells that also express high levels of Tbet and ware capable of promoting the differentiation of naive T cells into Th1 effectors [14] . The cognate interactions that occur between Tbet expressing and IFNγproducing T cells and B cells may result in the amplification of type 1 immune responses. Whether this mechanism contributes to AIH development requires further investigations.
Recent studies have shown that TBX21 T1993C polymorphism is associated with susceptibility to autoimmune diseases including AIH [23, 34] . To eliminate the possible effect of the T1993C polymorphism on the development of AIH, further detailed analysis of a large number of individuals including AIH patients carrying the CC genotype will be required.
YY1 is involved in repression and activation of several genes that play roles in various biological processes depending on the promoter sequence surrounding the YY1 binding site. Studies have shown YY1 positively regulated expression of several oncogenes, such as cMyc and cFos [35] . In addition, YY1 can positively regulate some tumor suppressor genes, such as p21 and p16 [36, 37] . However, one study showed that YY1 was a negative cell growth regulator by inhibiting cMyc function [38] . Interestingly, the promoter regions of genes that encode cytokines related to AIH, such as IL6, IL13 and IFNγ, contain consensus YY1 binding sequences and some of them can be regulated by this transcription factor [30, 39] . The transcriptional regulation of human TBX21 gene is complex, and several transcription factors such as SMAD4, SP1, and NFκB are involved [40, 41] . One potential YY1 binding site has been previously identified in the 2211 to +1 region of the TBX21 promoter, wherein T/CCCATTTT was the critical base sequence for YY1 binding and the TtoC mutation at the 5' terminal of this sequence resulted in an increase of YY1 binding. These regions have also been associated with silencing of promoter activity in transient transfection assays of transformed cell lines. Our studies indicate that the silencing activity of this region of theTBX21 promoter is also operational in native T cells and B cells in vivo and is probably regulated by YY1. Thus, we propose that YY1 could be a crucial transcription factor for Tbet expression which play a critical role in the inflammation in AIH.
In summary, we showed that the TBX211993C allele created a strong YY1binding site and decreased Tbet expression in CD4 + T and B cells. Reduced Tbet 
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Background background
Autoimmune hepatitis (AIH) is an autoimmune disease that involves aberrant B and T lymphocyte responses. T-box transcription factor (T-bet) is a key regulator for the lineage commitment in CD4 + T hepler 1 and B effector 1 cells by activating the hallmark production of interferon-γ (IFN-γ) . Although the role of T-bet has been studied in a variety of autoimmune diseases in mice, its relative importance in human AIH is not characterized. Detailed knowledge about T-bet-medicated immune responses will therefore enhance our understanding of the pathogenesis of AIH and might support the development of new immunomodulatory treatment approaches.
Research motivation
TBX21, which encodes T-bet, harbors many common polymorphisms at a strong linkage disequilibrium, and distinct TBX21 haplotypes are associated with autoimmune diseases in ethnically distinct populations. Our case-control study (84 cases and 318 control subjects) demonstrated a commone single nucleotide polymorphism (SNP) at the -1993 site of the TBX21 gene promoter that was associated with susceptibility to type 1 AIH (AIH-1) in a chinese population. Individuals carrying the -1993C allele had a decreased risk to AIH-1 compared with those without the -1993C allele (OR = 0.22; 95%CI: 0.09-0.56; P = 0.0016). Functional studies are necessary to dissect the mechanisms underlying the contribution of natural genetic variations to TBX21 dysregulation and the susceptibility to AIH-1 development.
Research objectives
In this study, the authors determined the characterization of transcription factor binding to the T-1993C SNP site of the TBX21 promoter in CD4+ T and B cell lines, and measured the expression of T-bet and IFN-γ in peripheral blood CD4 + T cells and B cells from active AIH-1 patients carrying -1993TC and -1993TT genotypes, compared with healthy controls carrying -1993TC and -1993TT genotypes, in an attempt to provide functional evidence for the association of the TBX21 T-1993C promoter polymorphism and AIH-1 development.
Research methods
In vivo, in vitro, and reporter analyses were performed to determine the function of transcription factor Yin-Yang 1(YY1) binding to the T-1993C element of the TBX21 promoter in human CD4
+ T and B cell lines. Flow cytometry and quantitative real-time PCR were used to analyze T-bet and IFN-γ expressions in CD4 + T cells, B cells and monocytes from the peripheral blood of AIH-1 patients including 5-1993TC and 15-1993TT genotype carriers, and healthy controls including 10-1993TC and 25-1993TT genotype carriers. Furthermore, knockdown of YY1 with siRNA was performed to investigate T-bet-medicated 
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Research results
TBX21
Research conclusions
Reduced T-bet and IFN-γ expression of circulating CD4 + T cells and B cells existed in the individuals carrying the -1993C allele compared with those without the -1993C allele, and played a protective role in AIH-1 development. Moreover, the authors propose a schematic model showing high-affinity binding of YY1 to the -1993C allele site leading to down-regulation of the TBX21 promoter activity, a mechanism for a promoter polymorphism affecting T-bet expression in AIH. 
Research perspectives
